The Basic Biology of Malignant Melanoma: Molecular Mechanisms of Disease Progression and Comparative Aspects

Journal of Veterinary Internal Medicine

Volumn 17, Issue 6, 2003, Pages 760-772

  Sulaimon, Shola S ^a,b   Kitchell, Barbara E ^a,c  

^a Veterinary Teaching Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Melanocytes; Metastasis; Tumor progression

Indexed keywords

ANGIOGENESIS; CANCER SUSCEPTIBILITY; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; COMPARATIVE STUDY; DISEASE COURSE; GENE EXPRESSION; GENETIC STABILITY; MALIGNANT NEOPLASTIC DISEASE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; NONHUMAN; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

ANIMALS; CELL CYCLE; CELL DIVISION; DISEASE PROGRESSION; DOG DISEASES; DOGS; GENETIC PREDISPOSITION TO DISEASE; MELANOCYTES; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

CANIS FAMILIARIS;

EID: 0346364913     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0760:TBBOMM>2.3.CO;2     Document Type: Review

References (101)

1. Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog. A retrospective survey of 361 cases. J Am Vet Med Assoc 1979; 175:567-571.
2. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996;209:98-102.
3. Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 1999;13:163-174.
4. Bar-Eli M. Gene regulation in melanoma progression by the Ap-2 transcription factor. Pig Cell Res 2001;14:78-85.
5. Sulaimon SS, Kitchell BE. Canine melanoma: Combating a destructive and deadly tumor. Vet Med 2001;96:931-942.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
7. Hahn W, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Cancer Rev 2002;2:331-341.
8. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-271.
9. Demunter A, Stas M, Degreef H, et al. Analysis of N-and K-Ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001;117:1483-1489.
10. Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions; correlation of point mutations with differentiation phenotype. Oncogene 1989;4: 1363-1374.
11. Platz A, Ringborg U, Mansson Brahme E, Magerlof B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994;4:169-177.
12. Tsao H, Zhang X, Fowlkes K, et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800-1804.
13. Papp T, Pemsel H, Zimmermann R, et al. Mutational of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999;36:610-614.
14. Watzinger F, Mayr B, Gamerith R, et al. Comparative analysis of ras proto-oncogene mutations in selected mammalian tumors. Mol Carcinog 2001;30:190-198.
15. Ahern TE, Bird RC, Bird AE, Wolfe LG. Overexpression of c-erB-2 and c-myc but not c-ras, in canine melanoma cell lines, is associated with metastatic potential in nude mice. Anticancer Res 1993; 13:1365-1371.
16. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. In: Franks LM, ed. Cancer Surveys: Advances and Prospects in Clinical Epidemiological Laboratory Oncology. London: Oxford University Press; 1990:645-671.
17. Senderowicz AM. The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002;7:12-19.
18. El Deiry WS, Tokino T, Velculescu VE, et al. WAF 1 is a potent mediator of p-53 suppression. Cell 1994;4:35-45.
19. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-546.
20. Ritt MG, Mayor J, Wojcieszyn J, et al. Sustained localization of p21/Waf-1 upon growth arrest induced by contact inhibition. Cancer Lett 2000;158:73-84.
21. Ritt MG, Wojcieszyn J, Modiano JF. Functional loss of p21/ Waf-1 in a case of benign canine multicentric melanoma. Vet Pathol 1998;35:94-101.
22. Kamb A, Gruis NA, Weaver FJ, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-440.
23. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin dependent kinase 4 inhibitor gene in multiple human cancers. Nature 1994;368:743-756.
24. Albino AP. Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995;7:162-169.
25. Gruis NA, van der Velden PA, Bergman W, Frants RR. Familial melanoma: CDKN2A and beyond. Invest Dermatol Symp Proc 1999; 4:50-54.
26. Fountain JW, Karayiorgou M, Taruscio D, et al. Genetic and physical map of the interferon region on chromosome 9p. Genomics 1992;14:105-112.
27. Beijersbergen RL, Carlee L, Kerhoven RM, Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Gene Dev 1995;9:1340-1353.
28. Mittnacht S. Control of pRb phosphorylation. Curr Opin Genet Dev 1998;8:21-27.
29. Pardee A. G1 events and regulation of cell proliferation. Science 1989;246:603-608.
30. Cress WD, Seto E. Histone deactylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
31. Morrison AJ, Sardet C, Herrera R. Retinoblastoma protein transcriptional repression through histone deacetylation of a single nucleosome. Mol Cell Biol 2002;2:856-865.
32. Nevins JR. Towards an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998;9:585-593.
33. Koenig A, Bianco R, Fosmire S, et al. Expression and significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002;39:458-472.
34. Modiano JF, Ritt M, Wojcieszyn J, Smith R. Growth arrest of melanoma cells is differentially regulated by contact inhibition and serum deprivation. DNA Cell Biol 1999;18:357-367.
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
36. Roels S, Tilman K, Ducatelle R. p53 expression and apoptosis in melanoma of dogs and cats. Res Vet Sci 2001;70:19-25.
37. Setoguchi A, Sakai T, Okuda M, et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res 2001; 62:433-439.
38. Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: The role of DNA base damage. Mol Carcinog 1990;3:188-197.
39. Tornaletti S, Pfeiffer GP. Slow repair of pyrimidine dimers at P53 mutation hot spots in skin cancer. Science 1994;263:1436-1438.
40. Moriwaki S, Ray S, Tarone RE, et al. The effect of donor age on the processing of UV-damaged DNA by cultures human cells: Reduced DNA repair capacity and increased DNA mutability. Mutat Res 1996;364:117-123.
41. Mitchell DL, Jen J, Cleaver JE. Relative induction of cyclobutane dimers and cytosine photohydrates in DNA irradiated in vitro and in vivo with ultraviolet-C and ultraviolet-B light. Photochem Photobiol 1991;54:741-746.
42. Setlow RB, Regan JD, German J, Carrier WL. Evidence that xeroderma pigmentosum cells do not perform the first step in the repair of ultraviolet damage to their DNA. Proc Natl Acad Sci U S A 1969; 64:1035-1041.
43. Liotta LA. Tumor invasion and metastases - Role of the extra cellular matrix: Hoads Memorial Award Lecture. Cancer Res 1986;46:1-7.
44. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; i:571-573.
45. Wong CW, Lee A, Shientag L, et al. Apoptosis: An early event in metastatic inefficiency. Cancer Res 2001;61:333-338.
46. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
47. Cory S, Adams JM. The BCL2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656.
48. Thornberry NA, Lazrbik Y. Caspases: Enemies within. Science 1998;281:1312-1316.
49. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999;6:1028-1042.
50. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001;69:2957-2964.
51. Takaoka A, Adachi M, Okuda H, et al. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997; 14:2971-2977.
52. Owen-Schuab LB, van Golen KL, Hill LL, Price JE. Fas and fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998;188:1717-1723.
53. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today 2000;6:163-169.
54. Tang A, Eller MS, Hara M, et al. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994;107:983-992.
55. Van Noorden CJF, Meade-Tollin LC, Bosman FT. Metastasis. Am Sci 1998;86:130-141.
56. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275: 1790-1792.
57. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion. Am J Pathol 2000;156:1515-1525.
58. Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89:2018-2022.
59. Li X, Regezi J, Ross P, et al. Integrin αvβ3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J Cell Sci 2001; 114:2665-2672.
60. McGregor BC, McGregor JL, Weiss LM, et al. Presence of cytoadhesins (IIb-IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 1989;92:495-499.
61. Hsu MY, Shin DT, Meier FE, et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998;153: 1435-1442.
62. VanBelle TJ, Albelda S, Tahin P, et al. Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999; 30:562-567.
63. Natali PG, Nicotra MR, Bartolazzi A, et al. Integrin expression in cutaneous malignant melanoma: Association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer 1993;54:68-72.
64. Li X, Chen B, Blystone SD, et al. Differential expression of alpha v integrins in K1735 melanoma cells. Invasion Metastasis 1998; 18:1-14.
65. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18: 345-357.
66. Bar-Eli M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997;173:275-278.
67. Luca M, Hunt B, Bucana CD, et al. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993;3:35-41.
68. Jean D, Gershenwald JE, Huang S, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273: 16501-16508.
69. Wu GJ, Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
70. Sera M, Pastor J, Domenzian C, Bassols A. Effect of transforming growth factor-beta1, insulin-like growth factor-1, and hepatocyte growth factor on proteoglycan production and regulation in canine melanoma cell lines. Am J Vet Res 2002;63:1151-1158.
71. Lander AD, Selleck SB. The elusive functions of proteoglycans: In vivo veritas. J Cell Biol 2000;148:227-232.
72. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann Med 1999;31:34-45.
73. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
74. Kurschat P, Mauch C. Mechanisms of metastasis. Clin Exp Dermatol 2000;25:482-489.
75. Kurschat P, Zigrino P, Nischt R, et al. Tissue inhibitor of matrix metalloproteinase-2 activation by modulation of membrane type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999;274:21056-21062.
76. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. Int J Mol Med 2000;6:391-407.
77. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenase-1 and -3 and their inhibitors TIMP-1 and TIMP-3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80:733-743.
78. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer 1997;59:467-473.
79. Hofmann UB, Westphal JR, Waas ET, et al. Expression and activation of matrix metalloproteinase and its co-localization with membrane type membrane type matrix metalloproteinase 1 (MT1-MMP) correlates with melanoma progression. J Pathol 2000;191:295-296.
80. Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216-1222.
81. Blavier L, Henriet P, Imren S, DeClerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann N Y Acad Sci 1999;878: 108-119.
82. Sounni NE, Baramova EN, Munaut C, et al. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int J Cancer 2002;98:23-28.
83. Hofmann UB, Westphal JR, Waas ET, et al. Matrix metalloproteinase in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase correlates with melanoma progression. Br J Cancer 1999;81:774-782.
84. Petitclerc E, Stromblad S, von Schalscha TL, et al. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999;59:2724-2730.
85. 3) and matrix metalloproteinase-2 (MMP-2) coincides with MMP 2 activation: Correlation with melanoma progression. J Invest Dermatol 2000;115:625-632.
86. Nikkola J, Vihnen P, Vlaykova T, et al. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease free survival in human metastatic melanoma. Int J Cancer 2002;97:432-438.
87. Wandel E, Grabhoff A, Mittag M, et al. Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro. Exp Dermatol 2000;9:34-41.
88. Wandel E, Raschke A, Hildebrandt G, et al. Fibroblasts enhance the invasive capacity of melanoma cells in vitro. Arch Dermatol Res 2002;293:601-608.
89. Graeven U, Rodeck U, Kaprinski S, et al. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001;61:7282-7290.
90. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;60:4932-4938.
91. Massi D, Franchi A, Borgognoni L, et al. Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic analysis. Virchows Arch 2002;440:22-28.
92. Graeven U, Fiedler W, Karpinski S, et al. Melanoma associated expression of vascular endothelial growth factor and its receptor FLT-1 and KDR. J Cancer Res Clin Oncol 1999;125:621-629.
93. Graeven U, Rodeck U, Karpinski S, et al. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001;61:7282-7290.
94. Brahimi-Horn C, Berra E, Pouysseur J. Hypoxia: The tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2002;11:S32-S36.
95. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999;80:1697-1707.
96. Ono M, Torisu H, Fukushi J, et al. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 1999;43:S69-S71.
97. Keping X. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-391.
98. Kunz M, Hartmann A, Lory E, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism of high tumor aggressiveness. Am J Pathol 1999;155:753-763.
99. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151:1105-1113.
100. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999;67:12-18.
101. Singh RK, Varney ML, Bucana CD, Johansson SL. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999;9:383-387.